Stock AWY0 PERCHERON THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Percheron Therapeutics Limited Börse Stuttgart

Equities

AWY0

AU0000317281

Market Closed - Börse Stuttgart
Other stock markets
 07:05:11 28/06/2024 BST 		5-day change 1st Jan Change
0.0482 EUR -0.62% Intraday chart for Percheron Therapeutics Limited -6.23% +40.12%
06-17 Percheron Therapeutics Appoints CFO MT
06-03 Percheron Therapeutics Names Chief Medical Advisor MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Antisense Therapeutics Appoints CEO/Managing Director
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023
Antisense Therapeutics Limited Announces Management Changes
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%
Antisense Therapeutics Appoints CEO/Managing Director
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director
Antisense Therapeutics Begins Dosing in Toxicology Study for Muscular Dystrophy Treatment
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency
Antisense Therapeutics Limited: Antisense Therapeutics: Tierstudie zur Gliedergürtelmuskeldystrophie R2 wurde eingeleitet
Antisense Therapeutics Starts Muscular Dystrophy Animal Study
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PER Stock
  4. AWY0 Stock
  5. News Percheron Therapeutics Limited
  6. Other languages